Search results
Showing 46 to 60 of 73 results for hepatocellular carcinoma
Evidence-based recommendations on melphalan chemosaturation with percutaneous hepatic artery perfusion and hepatic vein isolation for primary or metastatic cancer in the liver. This involves diverting the blood flow from the liver to the rest of the body while the drug is delivered directly into the liver.
View recommendations for HTG575Show all sections
Evidence-based recommendations on sofosbuvir (Sovaldi) for treating some types of chronic hepatitis C (HCV)
View recommendations for TA330Show all sections
ADI-PEG 20 for previously treated hepatocellular carcinoma [ID1025]
Discontinued Reference number: GID-TA10259
Durvalumab for untreated unresectable hepatocellular carcinoma [ID4068]
Discontinued Reference number: GID-TA11041
Our centralised approach to prioritising our guidance topics ensures that we produce guidance that's relevant, timely, accessible, and has demonstrable impact.
Past technology appraisal appeals and decisions
Nivolumab for previously treated advanced hepatocellular carcinoma [ID1141]
Discontinued Reference number: GID-TA10164
Discontinued Reference number: GID-TA11074
Evidence-based recommendations on bevacizumab (Avastin [originator] and biosimilars) with fluoropyrimidine-based chemotherapy for metastatic colorectal cancer.
Everolimus for preventing organ rejection in liver transplantation (TA348)
Evidence-based recommendations on everolimus (Certican) for preventing organ rejection in adults having a liver transplant.
Ledipasvir–sofosbuvir for treating chronic hepatitis C (TA363)
Evidence-based recommendations on ledipasvir–sofosbuvir (Harvoni) for treating some types (genotypes) of chronic hepatitis C.
LiMAx system for assessing the functional capacity of the liver (MIB168)
NICE has developed a medtech innovation briefing (MIB) on LiMAx system for assessing the functional capacity of the liver .
We have moved interventional procedures guidance 214 to become HealthTech guidance 138. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
We have moved interventional procedures guidance 2 to become HealthTech guidance 1. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
Obeticholic acid for treating primary biliary cholangitis (TA443)
Evidence-based recommendations on obeticholic acid (Ocaliva) for treating primary biliary cholangitis in adults.